Pre-Course: Challenging Cases in Colposcopy and Cervical Cancer Screening

01:00 PM - 05:00 PM

This course best serves healthcare professionals who have an intermediate to advanced level of medical knowledge and are interested in improving clinical outcomes of lower genital tract disorders. This course incorporates challenging cases in colposcopy and cervical cancer screening to help participants better manage patients within the frameworks of recent national recommendations published by ASCCP and other professional organizations.  Such recommendations include the ASCCP/ACS/ASCP Screening Guidelines for the Prevention and Early Detection of Cervical Cancer, the ASCCP Guidelines for the Management of Abnormal Screening Tests and Cancer Precursors, the ASCCP/SGO Interim Guidance on the Clinical Use of Primary HPV Testing for Cervical Cancer Screening, and the ASCCP/CAP Lower Anogenital Squamous Terminology (LAST). The challenging cases presented in this course will not only help participants understand how to use various guidelines in common clinical situations, but they will also explore acceptable management scenarios in situations for which the guidelines and algorithms may not apply. While these guidelines have been in clinical use for several years now, they are not without controversy. Faculty will explore some of the controversial aspects of these guidelines via lectures and interactive discussion. This postgraduate course will provide participants with a better understanding of the rationale for the recommendations and provide them with the opportunities to apply the guidelines in various common, and uncommon, specific cases and patient populations.

Educational objectives

Upon completion of this live educational activity, participants should be able to:

• Apply an understanding of the epidemiology and natural history of HPV and cervical cancer precursors to the rational screening of women for cervical cancer using the current consensus guidelines and interim guidance for use of primary HPV testing for cervical cancer screening;
• Apply the basic and clinical science underlying the Updated Consensus Management Guidelines to the individualized management of abnormal screening tests and pre-invasive histologic lesions;
• Manage women from special populations (e.g., adolescent, postmenopausal, and pregnant women) with abnormal screening results and CIN/AIS; and
• Interpret biopsy results that use the LAST terminology LSIL/HSIL rather than CIN1, CIN2, CIN3.

Course Level: Intermediate or Advanced

Course Director: Alan Waxman, MD, MPH

Speakers: Richard Guido, MD & Anna-Barbara Moscicki, MD